Preliminary study on expression and significance of plasminogen activator inhibitor-1 in endometrial carcinoma
10.3760/cma.j.issn.0254-9026.2014.10.016
- VernacularTitle:纤溶酶原激活物抑制剂在子宫内膜癌中表达及其意义的初步研究
- Author:
Shuai HUANG
;
Mingfei ZHENG
;
Sichen ZHANG
;
Shaowei WANG
- Publication Type:Journal Article
- Keywords:
Endometrial carcinoma;
Plasminogen activator inhibitor-1;
Endometrial hyperplasia;
Operation pathologic staging
- From:
Chinese Journal of Geriatrics
2014;33(10):1097-1099
- CountryChina
- Language:Chinese
-
Abstract:
Objective To research the relationship between the expression of PAI-1 and the clinical characteristics of the endometrial carcinoma.Methods We detected the level of the serum PAI-1 by ELISA in the patients with endometrial carcinoma,the patients with endometrial hyperplasia and the patients with normal endometrium.The expression of PAI-1 in endometrial carcinoma and normal endometrial tissues was observed by immunohistochemistry.Results The concentration of serum PAI-1 in patients with endometrial carcinoma was 18.64 ± 6.22 μtg/L,significantly higher than those of patients with endometrial hyperplasia (6.94 ± 2.87) μg/L and patients with normal endometrium (6.68 ± 2.13)μg/L (P=0.00).The expression rate of PAI-1 was 68.2％ (15/22) in endometrial carcinoma tissue,and 8.3％ (2/24) in normal endometrial tissue (P=0.00).Compared with the early endometrial carcinoma,the expression rate of PAI-1 in the advanced endometrial carcinoma was significantly higher (6/6 w 9/16,P=0.03).Conclusions The expression level of PAI-1 may be related to the stage of the endometrial carcinoma.
